Table 4.
(A) Analysis of median of overall survival received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously. (B) Death rate analysis received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously
| Group | Metastatic | Non- metastatic | ||
|---|---|---|---|---|
| Total number | BCc1(n = 14) | Placebo (n = 19) | BCc1(n = 12) | Placebo (n = 20) |
| (A) Median of overall survival analysis | ||||
| Median (days) | 302 | 107 | 482 | 265 |
| Std. error | 133.23 | 55.09 | –a | 27.769 |
| Median 95% CI (lower) | 40.87 | 0 | –a | 210.573 |
| Median 95% CI (upper) | 563.13 | 214.98 | –a | 319.427 |
| P-value for test of equality of survival distributions | 0.306 | 0.019 | ||
| HRb (BCc1/Placebo) |
0.589 | 0.019 | ||
| Stage (n) | ||||
| I | 0 | 0 | 0 | 0 |
| II | 0 | 0 | 0 | 3 |
| III | 0 | 0 | 11 | 10 |
| IIII | 14 | 19 | 0 | 0 |
| (B) Death rate analysis | ||||
| Death rate (%) | 50 | 53 | 0 | 35 |
Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)
aNo statistics are computed because all cases are censored
bUnivariate cox regression model